Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Investment Income: 2019-2023

Historic Non Operating Investment Income for Benitec Biopharma (BNTC) over the last 3 years, with Dec 2023 value amounting to -$1,000.

  • Benitec Biopharma's Non Operating Investment Income rose 66.67% to -$1,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$7,000, marking a year-over-year decrease of 16.67%. This contributed to the annual value of -$1,000 for FY2024, which is 66.67% up from last year.
  • According to the latest figures from Q4 2023, Benitec Biopharma's Non Operating Investment Income is -$1,000, which was down 200.00% from $1,000 recorded in Q2 2023.
  • Benitec Biopharma's 5-year Non Operating Investment Income high stood at $19,000 for Q2 2021, and its period low was -$23,000 during Q4 2021.
  • In the last 3 years, Benitec Biopharma's Non Operating Investment Income had a median value of -$1,000 in 2023 and averaged $181.82.
  • Per our database at Business Quant, Benitec Biopharma's Non Operating Investment Income slumped by 2,200.00% in 2021 and then skyrocketed by 200.00% in 2023.
  • Benitec Biopharma's Non Operating Investment Income (Quarterly) stood at -$1,000 in 2019, then remained steady at -$1,000 in 2020, then plummeted by 2,200.00% to -$23,000 in 2021, then spiked by 86.96% to -$3,000 in 2022, then soared by 66.67% to -$1,000 in 2023.
  • Its last three reported values are -$1,000 in Q4 2023, $1,000 for Q2 2023, and -$4,000 during Q1 2023.